3.02  -0.07 (-2.27%)		03-15 16:00
Open: 3.03 High: 3.09 Volume: 1,006,884		Pre. Close: 3.09 Low: 3 Market Cap: 109(M)

Short term
Mid term
Targets	6-month :	3.51	1-year :	4.1
Resists	First :	3	Second :	3.51
Pivot price	3
Supports	First :	3	Second :	3
MAs	MA(5) :	3	MA(20) :	3
	MA(100) :	3.06	MA(250) :	2.83
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 42.3
52-week	High :	3.19	Low :	1.66

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CYT ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.02 - 3.03	3.03 - 3.04
Low:	2.97 - 2.99	2.99 - 3.01
Close:	2.98 - 3.01	3.01 - 3.04

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Wed, 20 Mar 2024
Cyteir Therapeutics Formalizes Dissolution and Asset Payout Plan - TipRanks.com - TipRanks

Thu, 07 Mar 2024
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq - Business Wire

Fri, 30 Jun 2023
Cyteir (CYT) Stock Surges After Announcing Plans to Dissolve - Bloomberg

Fri, 30 Jun 2023
Cyteir calls it quits after months of cost cutting - Fierce Biotech

Fri, 30 Jun 2023
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and ... - Yahoo Finance

Fri, 20 Jan 2023
Cyteir lays off 70% after further narrowing cancer drug goals - Fierce Biotech

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	36 (M)
Shares Float	11 (M)
Held by Insiders	6.6 (%)
Held by Institutions	76.8 (%)
Shares Short	320 (K)
Shares Short P.Month	346 (K)

EPS	-0.94
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.47
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-14.5 %
Return on Equity (ttm)	-23.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.93
Qtrly Earnings Growth	0 %
Operating Cash Flow	-26 (M)
Levered Free Cash Flow	-14 (M)

PE Ratio	-3.24
PEG Ratio	0
Price to Book value	0.86
Price to Sales	0
Price to Cash Flow	-4.21

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.